文献速递淋巴瘤

泽布替尼治疗复发/难治性套细胞淋巴瘤:2期研究长期疗效与安全性结果

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
PubMed 文献 · Blood · 2022-01-01

这项多中心、开放标签、2期注册试验纳入86例复发/难治性套细胞淋巴瘤患者,口服泽布替尼160 mg每日两次。中位随访35.3个月后,总缓解率83.7%,完全缓解率77.9%,中位无进展生存期33.0个月,36个月总生存率74.8%,安全性特征与延长随访前基本一致。

要点

  • 中位随访35.3个月,总缓解率83.7%,完全缓解率77.9%,中位缓解持续时间未达到。
  • 中位无进展生存期33.0个月(95%CI 19.4-未评估),36个月无进展生存率和总生存率分别为47.6%和74.8%。
  • 感染、中性粒细胞减少和出血发生率在治疗前6个月最高,之后下降;未报告心房颤动/扑动、≥3级心脏不良事件、第二原发恶性肿瘤或肿瘤溶解综合征。

核心结论

  • 延长随访后,泽布替尼在复发/难治性套细胞淋巴瘤中显示出持久的缓解和良好的安全性特征。

研究设计与样本

  • 多中心、开放标签、2期注册试验,纳入86例复发/难治性套细胞淋巴瘤患者,口服泽布替尼160 mg每日两次。
  • 主要终点为按Lugano 2014标准评估的总缓解率。
  • 试验在ClinicalTrials.gov注册,注册号为NCT03206970。

主要发现

  • 中位随访35.3个月,总缓解率83.7%,完全缓解率77.9%,中位缓解持续时间未达到。
  • 中位无进展生存期33.0个月(95%CI 19.4-未评估)。
  • 36个月无进展生存率47.6%(95%CI 36.2-58.1),36个月总生存率74.8%(95%CI 63.7-83.0)。
  • 最常见(≥20%)的任何级别不良事件为中性粒细胞计数降低(46.5%)、上呼吸道感染(38.4%)、皮疹(36.0%)、白细胞计数降低(33.7%)和血小板计数降低(32.6%),其中大多数为1/2级事件。
  • 最常见(≥10%)的≥3级不良事件为中性粒细胞计数降低(18.6%)和肺炎(12.8%);感染、中性粒细胞减少和出血发生率在治疗前6个月最高,之后下降;未报告心房颤动/扑动、≥3级心脏不良事件、第二原发恶性肿瘤或肿瘤溶解综合征。

关键数值与推荐

  • 总缓解率83.7%,完全缓解率77.9%,中位缓解持续时间未达到。
  • 中位无进展生存期33.0个月(95%CI 19.4-未评估)。
  • 36个月无进展生存率47.6%(95%CI 36.2-58.1),36个月总生存率74.8%(95%CI 63.7-83.0)。
  • 最常见(≥20%)的任何级别不良事件:中性粒细胞计数降低46.5%、上呼吸道感染38.4%、皮疹36.0%、白细胞计数降低33.7%、血小板计数降低32.6%。
  • 最常见(≥10%)的≥3级不良事件:中性粒细胞计数降低18.6%、肺炎12.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have received ≥1 prior therapy. We report the long-term safety and efficacy results from the multicenter, open-label, phase 2 registration trial of zanubrutinib. Patients (n = 86) received oral zanubrutinib 160 mg twice daily. The primary endpoint was the overall response rate (ORR), assessed per Lugano 2014. After a median follow-up of 35.3 months, the ORR was 83.7%, with 77.9% achieving complete response (CR); the median duration of response was not reached. Median progression-free survival (PFS) was 33.0 months (95% confidence interval [CI], 19.4-NE). The 36-month PFS and overall survival (OS) rates were 47.6% (95% CI, 36.2-58.1) and 74.8% (95% CI, 63.7-83.0), respectively. The safety profile was largely unchanged with extended follow-up. Most common (≥20%) all-grade adverse events (AEs) were neutrophil count decreased (46.5%), upper respiratory tract infection (38.4%), rash (36.0%), white blood cell count decreased (33.7%), and platelet count decreased (32.6%); most were grade 1/2 events. Most common (≥10%) grade ≥3 AEs were neutrophil count decreased (18.6%) and pneumonia (12.8%). Rates of infection, neutropenia, and bleeding were highest in the first 6 months of therapy and decreased thereafter. No cases of atrial fibrillation/flutter, grade ≥3 cardiac AEs, second primary malignancies, or tumor lysis syndrome were reported. After extended follow-up, zanubrutinib demonstrated durable responses and a favorable safety profile in R/R MCL. The trial is registered at ClinicalTrials.gov as NCT03206970.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022. PMID: 35303070. doi:10.1182/blood.2021014162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。